Articles By Rachel Tate, DO
Complementary and Alternative Therapies in Psoriasis and Psoriatic Arthritis
It’s been reported that approximately one-third to one-half of patients with psoriatic arthritis will try supplements and other complementary and alternative medicinal (CAM) practices without discussing with their rheumatologists. Of those, nearly 90% of PsA patients using CAM report benefits! Here is your updated review on common supplement data in psoriasis and PsA.
Read ArticleMDA: Aiming for Perfection in PsA
When it comes to psoriatic arthritis clinical trials such as TICOPA (tight control in PsA) have consistently shown that treating to target correlates with improved disease domain and patient reported outcomes. Minimal disease activity (MDA) has become an oft used target and outcome in PsA trials. While many of us measure and record a variety of measures in our patient charts, we may be on our way to demonstrating MDA in practice. Here is a quick review of MDA components and how to capture them for your patients.
Read ArticlePolyautoimmunity: axSpA and Familial Mediterranean Fever
Mysteries behind polyautoimmunity have confounded rheumatologists for decades. One such association, the co-existence of Familial Mediterranean Fever (FMF) and axial spondyloarthritis (axSpA), remains rare. In fact, we believe the rate to be between 0.5% and 7.5%.
Read ArticleThree Healthcare Hashtags You Should Follow
I've sent more than 2,000 tweets since joining Twitter in July 2010. Even better, I've read (and sometimes shared) thousands of other educational, informative and sometimes humorous tweets from fellow rheumatologists, physicians, healthcare providers and others around the world. While following individuals and organizations relevant to you is important, so is following hashtags. Here are three I recommend.
Read ArticleICYMI: New GRAPPA 2021 PsO and PsA Treatment Recommendations
The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. The goal (as per 2009 recommendations) was “To develop recommendations, based upon the best scientific evidence, for the optimal treatment of patients with PsA” Dr. Laura Coates, Oxford detailed in abstract #OP0229. Since the last update in 2015, there have been multiple changes, which are highlighted here.
Read ArticleQ-DAPSA for Measuring Disease Activity in PsA
Given its multiple domains, there remains much discussion over the best disease activity scoring method in PsA. The proverbial "holy grail" would be a measure that is quick, intuitive, domain comprehensive and validated.
Read ArticleNew GRAPPA 2021 PsO and PsA Treatment Recommendations
The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021.
Read ArticleHLA B27 Iritis - RNL 2021 Highlights
The Spondyloarthritis Advances pod presented during the RheumNow Live 2021 conference featured three speakers, including an excellent lecture by Dr. Robert Wang, ophthalmology, on HLA B27 iritis and practical tips for rheumatologists.
Read ArticleRWCS Highlights - Day 4
As another year at RWCS in Maui wrapped up, I’m so thankful I had the opportunity to participate remotely. Here are my day 4 #RWCS2021 pearls from the Novel Therapies Year in Review (RA, SLE, OA); novel concepts in pediatric rheumatology; and post-COVID telerheumatology sessions.
Read Article